Has Christopher Duma, MD received payments from drug or device companies?

Yes. Drug and device makers reported $142,231 in general payments to Christopher Duma, MD across 227 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Duma, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Duma, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Duma, MD

Neurological Surgery · Newport Beach, CANPI 1306870845

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $113,749 of the $142,231 with a category attached, or 80.0%. Longeviti Neuro Solutions Inc accounts for 88.7% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $117,427, more than ten times the $2,978 reported in 2019. Among neurological surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$142,231in general payments, 2019–2025

Across 227 payments — averaging $626.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Longeviti Neuro Solutions Inc$126K
Medtronic$8K
Osteomed LLC$3K
Boston Scientific$763
Insightec,inc$642
NX Development Corp.$639
plus $4K from 24 others

What the payments were for

Consulting fees$13,3009%
Speaking & faculty fees$113,74980%
Food & beverage$15,04011%
Education$1430%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Longeviti Neuro Solutions Inc	15	$126,111
Medtronic(2 entities)	103	$7,629
Osteomed LLC	3	$2,784
Boston Scientific	16	$763
Insightec,inc	11	$642
NX Development Corp.	2	$639
Abbott	16	$632
Visionrt, Inc.	1	$523
Surgical Theater. Inc.	2	$317
UCB, Inc.	11	$312
Lilly USA, LLC	7	$270
Aesculap, Inc.	4	$214
Zap Surgical Systems, Inc.	1	$201
Monteris Medical Corporation	1	$185
AbbVie(2 entities)	8	$160
Stryker	4	$98
GT Medical Technologies, Inc	2	$97
Merck	4	$87
Novocure Inc.	1	$84
Irras USA, Inc.	1	$78
Arbor Pharmaceuticals, Inc.	4	$77
Integra Lifesciences Corporation	2	$75
Cerapedics Inc.	1	$51
Elekta, Inc.	1	$45
Terumo BCT, Inc.	1	$44
Johnson & Johnson	1	$37
Biogen	1	$28
Analogic Corporation	1	$25
Lemaitre Vascular, Inc.	1	$15
Kls-martin L.p.	1	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$142,231 in reported general payments places this provider in the 90th percentile of 773 neurological surgery providers in California.

See all neurological surgery providers in California →

Medicare billing

Part B allowed, 2024

$488,919

Medicare patients

488

Services billed

1,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	12	$62

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Newport Beach

Robert LouisNewport Beach$932K
Christopher AmesSan Francisco$7.1M
Larry KhooLos Angeles$2.8M
Samy AbdouSan Diego$2.4M
Bret AbshireMurrieta$2.3M
William TaylorSan Diego$2.1M
Tooraj GravoriEncino$2M
Ali MesiwalaRancho Cucamonga$1.5M
Joseph OsorioSan Diego$1.3M
Ian JohnsonFresno$1.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →